Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Egging"'
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::577fecc3721cf52f00190b2f91911f37
https://doi.org/10.1158/1535-7163.22502829.v1
https://doi.org/10.1158/1535-7163.22502829.v1
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Details are given of the synthesis of SYD983 and the non-binding control, preparation of fluorescently-labeled SYD983, bioanalysis of SYD983 using SEC, HIC, and RP-HPLC, functional assays like an ADCC assay and internalization, and details on the PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d71b8b769e05a9d69d5154dd46d72d7
https://doi.org/10.1158/1535-7163.22502832.v1
https://doi.org/10.1158/1535-7163.22502832.v1
Autor:
Viswanath Devanarayan, Simon Cowen, Michaela Golob, Daniel Kramer, Jim McNally, Venke Skibeli, David Egging, Marianne Scheel Fjording, Robert Nelson, Timo Piironen, Thomas Emrich, Joao Pedras-Vasconcelos, Denise Sickert, Philip Timmerman, James Munday, Joanne Goodman
Publikováno v:
Bioanalysis. 10:197-204
European Bioanalysis Forum Workshop, Lisbon, Portugal, September 2016: At the recent European Bioanalysis Forum Focus Workshop, ‘current analysis of immunogenicity: best practices and regulatory hurdles’, several important challenges facing the b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49dc3d9deb4a5a170c69c7cd04d46fed
https://doi.org/10.4155/bio-2017-4971
https://doi.org/10.4155/bio-2017-4971
Autor:
Karin Lubbers-Geuijen, Tinie van Boekel, Jochem Eigenhuijsen, Benny de Wit, Roel Mulder, Jos Verhagen, Karin de Laat-Arts, Marijn Buurman, David Egging
Publikováno v:
Bioanalysis. 10(16)
Aim: Detection and characterization of antidrug antibodies (ADA) play a key role in understanding the relation of ADA with safety and efficacy. Positive controls (PCs) are used to estimate the sensitivity and assay sensitivity in the presence of drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068a103fef6b3f41497f3a3800ad363d
https://pubmed.ncbi.nlm.nih.gov/30130133
https://pubmed.ncbi.nlm.nih.gov/30130133
Autor:
Evelyn van den Tweel, Jeffrey A. Cohen, Christian Wolf, Krzysztof Selmaj, Roel Mulder, Frederik Barkhof, David Egging, Janine Oberye, Anna N. Belova, Norbert P Koper
Publikováno v:
Multiple Sclerosis, 23(14), 1909-1917. SAGE Publications Ltd
Selmaj, K, Barkhof, F, Belova, A N, Wolf, C, van den Tweel, E R W, Oberyé, J J L, Mulder, R, Egging, D F, Koper, N P, Cohen, J A & on behalf of the GATE study group 2017, ' Switching from branded to generic glatiramer acetate : 15-month GATE trial extension results ', Multiple Sclerosis, vol. 23, no. 14, pp. 1909-1917 . https://doi.org/10.1177/1352458516688956
Multiple Sclerosis (Houndmills, Basingstoke, England)
Selmaj, K, Barkhof, F, Belova, A N, Wolf, C, van den Tweel, E R W, Oberyé, J J L, Mulder, R, Egging, D F, Koper, N P, Cohen, J A & on behalf of the GATE study group 2017, ' Switching from branded to generic glatiramer acetate : 15-month GATE trial extension results ', Multiple Sclerosis, vol. 23, no. 14, pp. 1909-1917 . https://doi.org/10.1177/1352458516688956
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone® (GATE) trial. Objective: To evaluate efficacy, safety, and tolerability of prolonged generic gla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e9ed4de2c4d60a6e7d9e3d5dae9379
https://research.vumc.nl/en/publications/6d1e79f7-6544-4e88-998d-f081c2bec390
https://research.vumc.nl/en/publications/6d1e79f7-6544-4e88-998d-f081c2bec390
Publikováno v:
American journal of medical genetics. Part C, Seminars in medical genetics. (1)
Tenascin-X is an extracellular matrix protein initially identified because of its overlap with the human CYP21B gene. Because studies of gene and protein function of other tenascins had been poorly predictive of essential functions in vivo, we used a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d6004e5f52b326b59d3fea7edf860c
https://pubmed.ncbi.nlm.nih.gov/16278880
https://pubmed.ncbi.nlm.nih.gov/16278880